Novel imaging techniques such as positron emission tomography (PET) with specific radiopharmaceuticals targeting prostate-specific membrane antigen (PSMA), that avidly accumulates in PC foci, have improved tumour staging [9] and have led to earlier detection and localization of specific metastases at the time of BCR [2, 10–12]. This evidence concerns the gene FOLH1 and pachyonychia congenita.